In a headline-grabbing move that’s shaking up the dental device sector, ArchiMed, a France-based healthcare investment powerhouse, has announced plans to acquire ZimVie Inc. for a jaw-dropping $730 million. The all-cash deal, unveiled Monday, will see ArchiMed scoop up all outstanding shares of the Florida-headquartered dental implant company at $19 per share—a staggering 99% premium over ZimVie’s 90-day average trading price.
The market didn’t take long to react. ZimVie’s stock surged 122%, rocketing to $18.74 per share in Monday afternoon trading, proving that investors are already biting into ArchiMed’s bold vision.
Latham & Watkins and Cravath Steer Legal Strategy
Latham & Watkins LLP is advising ArchiMed on the blockbuster deal, while Cravath Swaine & Moore LLP, ZimVie’s longtime legal partner, is guiding the dental company. The Cravath team is led by seasoned partners Robert I. Townsend III and Matthew G. Jones.
The deal includes a 40-day “go-shop” clause, allowing ZimVie to solicit competing offers until August 29, with Centerview Partners serving as financial advisor during the process.
